HIGHLIGHTS
- Who: Hongwei Cheng et al. from the University of Macau, China have published the Article: Dif culty in differentiating liver injury from an immune checkpoint inhibitor from, in the Journal: (JOURNAL)
SUMMARY
Immune checkpoint inhibitors (ICIs) are currently being extensively utilized in the treatment of malignancies and have yielded promising outcomes (Benitez et_al, 2020). Frontiers in Pharmacology frontiersin.org 10.3389/fphar.2024.1453595 published data on ICI-induced DILI (Zen et_al, 2020), which indicate that infiltrating lymphocytes in the portal vein region consist of CD4+ helper T_cells and/or CD8+ cytotoxic T_cells . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.